Study of lipid based nanoparticles as carriers for anticancer ruthenium metallodrugs

• Grant number: 15/24252-4
• Support type: Scholarships abroad - Research Internship - Doctorate (Direct)
• Effective date (Start): May 01, 2016
• Effective date (End): April 30, 2017
• Field of knowledge: Physical Sciences and Mathematics - Chemistry - Inorganic Chemistry
• Principal researcher: Denise de Oliveira Silva
• Grantee: Samara Rodrigues Alves
• Supervisor abroad: Xiao Yu Wu
• Home Institution: Instituto de Química (IQ). Universidade de São Paulo (USP). São Paulo , SP, Brazil
• Research place: University of Toronto (U of T), Canada
• Associated to the scholarship: 14/23481-7 - Study of lipid-based nanoparticles as carriers for anticancer ruthenium metallodrugs, BP.DD

Abstract

Ruthenium compounds have received great attention in the field of metallodrugs because of their potential as anticancer agents. Complexes containing Ru2(II,III) dimetal cores coordinated to non-steroidal anti-inflammatory drugs (NSAIDs) developed in our research group have shown promising results in studies in vitro and in vivo in glioma models, such as the glioblastoma multiforme, a highly malignant brain cancer. The main objective of this proposal for Sandwich stage is to investigate the feasibility of developing hybrid nanoparticle lipid systems with Ru2(II,III)-NSAID complexes aiming to promote loading and sustained release of the metallodrugs in the brain. Lipid nanoparticles developed by Dr. Wu's group, such as lipid-terpolymer nanoparticles, were found to be capable of crossing the blood brain barrier, thus showing potential for treatment of gliomas, and allowing, among other things, to increase the intracellular and intratumor bioavailability and to decrease the systemic toxicity of antitumor drugs. In this context, the main goals of this research plan are: 1) to develop methodology for preparation of lipid nanoparticles, as Solid Lipid Nanoparticles (SLNs) and lipid-terpolymer nanoparticles, containing the metallodrugs; 2) to characterize the hybrid nanoparticles by diverse techniques; 3) to investigate the feasibility of releasing the metallodrugs from the hybrid materials; 4) to perform studies in vitro in order to verify the potential application of the new systems in anticancer treatments. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

ALVES, SAMARA RODRIGUES; COLQUHOUN, ALISON; WU, XIAO YU; SILVA, DENISE DE OLIVEIRA. Synthesis of terpolymer-lipid encapsulated diruthenium(II,III)-anti-inflammatory metallodrug nanoparticles to enhance activity against glioblastoma cancer cells. Journal of Inorganic Biochemistry, v. 205, APR 2020. (14/23481-7, 15/24252-4, 14/23047-5)

ALVES RICO, SAMARA R.; ABBASI, AZHAR Z.; RIBEIRO, GEISE; AHMED, TAKSIM; WU, XIAO YU; SILVA, DENISE DE OLIVEIRA. Diruthenium(II,III) metallodrugs of ibuprofen and naproxen encapsulated in intravenously injectable polymer-lipid nanoparticles exhibit enhanced activity against breast and prostate cancer cells. NANOSCALE, v. 9, n. 30, p. 10701-10714, AUG 14 2017. (15/24252-4, 14/23047-5, 14/23481-7, 11/06592-1)